Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.59 |
| ▸ | MVD | P53602 | 4/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28234823 | 0.98 | BTN3A1 (0.57) | BTN3A1MVDLPAR3LPAR1LPAR2 | |
| SCHEMBL6424549 | 0.96 | BTN3A1 (0.55) | BTN3A1MVDLPAR3LPAR1LPAR2 | |
| SCHEMBL13133478 | 0.96 | BTN3A1 (0.55) | BTN3A1MVDLPAR3LPAR1LPAR2 | |
| SCHEMBL309468 | 0.90 | BTN3A1 (0.47) | BTN3A1MVDLPAR3LPAR1LPAR2 | |
| SCHEMBL379135 | 0.86 | LPAR3 (0.57) | BTN3A1MVDLPAR3LPAR1LPAR2 | |
| SCHEMBL7531145 | 0.85 | BTN3A1 (0.61) | BTN3A1MVDFDPSBLMTDP1 | |
| SCHEMBL497177 | 0.85 | LPAR3 (0.46) | BTN3A1LPAR3LPAR1LPAR2 | |
| Ammonia Solution, Strong SCHEMBL28249850 | 0.85 | LPAR3 (0.55) | BTN3A1MVDLPAR3LPAR1LPAR2 | |
| SCHEMBL2869539 | 0.85 | LPAR3 (0.67) | BTN3A1MVDLPAR3LPAR1LPAR2 | |
| SCHEMBL11809290 | 0.84 | CYP3A4 (0.44) | BTN3A1MVDLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112993289-A | Lithium/carbon fluoride battery, electrolyte thereof and use method thereof | 中国科学院大连化学物理研究所 | 2021-06-18 | — | — | CN | claimed |
| US-9453244-B2 | Method for producing a monoalkene by enzymatic conversion of an alkyl monoester | GLOBAL BIOENERGIES (FR) | 2016-09-27 | — | — | US | claimed |
| US-20150159177-A1 | METHOD FOR PRODUCING A MONOALKENE BY ENZYMATIC CONVERSION OF AN ALKYL MONOESTER | GLOBAL BIOENERGIES (FR) | 2015-06-11 | — | — | US | claimed |
| EP-2867365-A1 | PROCESS FOR PRODUCING A C2-C10 MONOALKENE EMPLOYING A TERPENE SYNTHASE OR A PRENYL TRANSFERASE | Scientist of Fortune S.A. (LU) | 2015-05-06 | — | — | EP | claimed |
| WO-2014001517-A1 | PROCESS FOR PRODUCING A C2-C10 MONOALKENE EMPLOYING A TERPENE SYNTHASE OR A PRENYL TRANSFERASE | SCIENTIST OF FORTUNE S.A. (LU) | 2014-01-03 | — | — | WO | claimed |
| US-5639653-A | ADMINISTERING MONOALKYL- OR ALKENYL-PYROPHOSPHATE TO MAMMAL TO STIMULATE LYMPHOCYTE CELL GROWTH AND ENHANCE IMMUNE RESPONSE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSTIY (US) | 1997-06-17 | — | — | US | claimed |
| EP-4277731-A1 | MEMBRANE FOR WATER FILTRATION | Aquaporin A/S (DK) | 2023-11-22 | — | — | EP | disclosed |
| CN-116925146-A | Preparation method of 1-butyl phosphoric acid cyclic anhydride | 联化科技股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116745025-A | membrane for water filtration | 水通道蛋白有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-111635434-B | Synthesis method of 1-propylphosphoric cyclic anhydride | 苏州昊帆生物股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2022152748-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2022-07-21 | — | — | WO | disclosed |
| WO-2010001078-A2 | PRODUCTION OF ALKENES BY ENZYMATIC DECARBOXYLATION OF 3-HYDROXYALKANOIC ACIDS | MARLIERE PHILIPPE (FR) | 2010-01-07 | — | — | WO | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-5902793-A | ADMINISTERING TO MAMMAL GAMMA-MONOALKYL- OR GAMMA-ALKENYL-NUCLEOSIDE OR DEOXYNUCLEOSIDE TRIPHOSPHATE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-05-11 | — | — | US | disclosed |
| US-5639653-A | ADMINISTERING MONOALKYL- OR ALKENYL-PYROPHOSPHATE TO MAMMAL TO STIMULATE LYMPHOCYTE CELL GROWTH AND ENHANCE IMMUNE RESPONSE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSTIY (US) | 1997-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | HSPA5, HSPBP1, RRBP1 | BTN3A1 2857/4885MVD 3262/4885LPAR3 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.